With no new kidney-protective therapies approved in T1D for over 3 decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.
Katherine R. Tuttle, MD, FASN, FACP, FNKF
Advertisement
Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health and professor of medicine at the University of Washington School of Medicine.
Articles by Katherine R. Tuttle, MD, FASN, FACP, FNKF
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
3
Workforce Preparation for Fall Immunization Season Starts Now
4
Antibody-Drug Conjugates and HER2 Guidelines Are Reshaping Breast Cancer Treatment
5